What is the current valuation of the non invasive-prenatal-testing market in Germany as of 2024?

The overall market valuation was 109.2 $ Million in 2024. Read More

What is the projected market valuation for the non invasive-prenatal-testing market in Germany by 2035?

The projected valuation for 2035 is 245.0 $ Million. Read More

What is the expected CAGR for the non invasive-prenatal-testing market in Germany during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 7.62 %. Read More

Which companies are considered key players in the non invasive-prenatal-testing market in Germany?

Key players in the market include Illumina, Roche, Natera, Fulgent Genetics, LabCorp, Quest Diagnostics, Haplogen, and Genomic Health. Read More

What are the main segments of the non invasive-prenatal-testing market in Germany?

The main segments include Cell-Free Fetal DNA Testing, Biochemical Markers Testing, and Ultrasound Screening. Read More

How did the Cell-Free Fetal DNA Testing segment perform in 2024?

The Cell-Free Fetal DNA Testing segment had a valuation range of 40.0 to 90.0 $ Million in 2024. Read More

What applications are covered in the non invasive-prenatal-testing market in Germany?

Applications include Trisomy Detection, Single Gene Disorders, and Sex Chromosome Abnormalities. Read More

What is the valuation range for the Trisomy Detection application in 2024?

The Trisomy Detection application had a valuation range of 40.0 to 90.0 $ Million in 2024. Read More

Which end users are primarily involved in the non invasive-prenatal-testing market in Germany?

Primary end users include Hospitals, Diagnostic Laboratories, and Research Institutions. Read More

What was the valuation for Diagnostic Laboratories in the non invasive-prenatal-testing market in 2024?

The valuation for Diagnostic Laboratories was between 45.0 and 100.0 $ Million in 2024. Read More

Germany Non Invasive Prenatal Testing Market

ID: MRFR/MED/49123-HCR

200 Pages

Nidhi Mandole

Last Updated: April 06, 2026

Germany Non-Invasive Prenatal Testing Market Research Report: Size, Share, Trend Analysis By Test Type (Cell-Free DNA Testing, Biochemical Testing, Combined Screening), By Applications (Fetal Gender Determination, Chromosomal Abnormalities Screening, Rhesus Disease Screening), By Technology (Next Generation Sequencing, Microarray Analysis, Polymerase Chain Reaction) and By End Users (Hospitals, Diagnostic Laboratories, Direct-to-Consumer Companies) - Growth Outlook & Industry Forecast 2025 To 2035

Germany Non Invasive Prenatal Testing Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Million)
  1. 4.1.1 Cell-Free Fetal DNA Testing
  2. 4.1.2 Biochemical Markers Testing
  3. 4.1.3 Ultrasound Screening
2. 4.2 Pharmaceutical, BY Application (USD Million)
  1. 4.2.1 Trisomy Detection
  2. 4.2.2 Single Gene Disorders
  3. 4.2.3 Sex Chromosome Abnormalities
3. 4.3 Pharmaceutical, BY Technology (USD Million)
  1. 4.3.1 Next-Generation Sequencing
  2. 4.3.2 Microarray Analysis
  3. 4.3.3 Massively Parallel Sequencing
4. 4.4 Pharmaceutical, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Diagnostic Laboratories
  3. 4.4.3 Research Institutions
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Illumina (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Natera (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Fulgent Genetics (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 LabCorp (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Quest Diagnostics (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Haplogen (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Genomic Health (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GERMANY MARKET ANALYSIS BY TYPE
3. 6.3 GERMANY MARKET ANALYSIS BY APPLICATION
4. 6.4 GERMANY MARKET ANALYSIS BY TECHNOLOGY
5. 6.5 GERMANY MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY TECHNOLOGY, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Germany Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Million, 2025-2035)

Cell-Free Fetal DNA Testing
Biochemical Markers Testing
Ultrasound Screening

Pharmaceutical By Application (USD Million, 2025-2035)

Trisomy Detection
Single Gene Disorders
Sex Chromosome Abnormalities

Pharmaceutical By Technology (USD Million, 2025-2035)

Next-Generation Sequencing
Microarray Analysis
Massively Parallel Sequencing

Pharmaceutical By End User (USD Million, 2025-2035)

Hospitals
Diagnostic Laboratories
Research Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”